FDA on Novartis data manipulation controversy: ‘We happened to be lucky’

FDA on Novartis data manipulation controversy: ‘We happened to be lucky’

Source: 
Stat
News Tags: 
snippet: 

Since the Food and Drug Administration blasted Novartis (NVS) earlier this month over data manipulation, one of the major questions looming over the matter has been why the agency came down so publicly on the drug maker. The answer, according to a top FDA official, is because the stakes were too high to do otherwise.